AcaHealth Pharma & Biotech Co.,LTD

長安醫藥生技 Innovative R&D

Neurodegenerative diseseas

Activating mitochondrial function and haemoglobin expression with EH-201, an inducer of erythropoietin in neuronal cells,reverses memory impairment.
Lin-Yea Horng, Pei-Lun Hsu, Li-Wen Chen, Wang-Zou Tseng, Kai-Tin Hsu, Chia-Ling Wu and Rong-Tsun Wu
British Journal of Pharmacology, 172: 4741, 2015.
CONCLUSIONS AND IMPLICATIONS: The induction of endogenous erythropoietin in neuronal cells by inducers such as EH-201 might be a therapeutic strategy for memory impairment in neurodegenerative disease, physiological ageing or traumatic brain injury.
Advantage of AH-501-NDD :
Our publication in British of Pharmacology was chosen by World Biomedical Frontiers in section of Alzheimer because of its innovation and potential for significant impact. (Oct 27, 2015)
There were over 1,200 clinical trials in Alzheimer’s disease failed so far.
AH-501-NDD is an endogenous EPO inducer in neural cells and produced tissue specific factor NGF and BDNF for activating autophagy to remove the abnormal aggregate proteins in a cellular huntington’s model.
Global market for Neurodegenerative diseases
GBI Research 2016
The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%.
Copyright © 2020 長安醫藥生技 AcaHealth Pharma & Biotech Company

WebMake SiteBuild | HiYP B2B Service | TaiwanDNS